Date of study period: April 12 May 7, 2010 and August September, 2010
|
|
- Victoria Hopkins
- 6 years ago
- Views:
Transcription
1 Classification of antiretroviral therapy failure using immunologic and clinical versus virologic monitoring in HIV-infected children and adolescents in Cambodia Date of study period: April 12 May 7, 2010 and August September, 2010 Location/Foreign Institution: Angkor Hospital for Children (AHC), Siem Reap, Kingdom of Cambodia. AHC is a pediatric teaching hospital funded by Friends without a Border, a New York based non-governmental organization (NGO) founded by Kenro Izu in 1996 whose sole initial aim was to build a pediatric hospital in Siem Reap, Cambodia. Construction was completed in 1999 and over 650,000 children have been treated in the subsequent decade of operation. The AHC Medical Education Center, a joint project, formally trains over 1,000 local doctors and nurses annually. Staffing is provided by full-time Cambodian directors of nursing, surgery, and pediatrics, with administrative leadership from ex-pat stakeholders. The hospital complex provides 24 hour emergency care, outpatient and inpatient clinical services, as well as basic surgical and dental services. Outpatient services include pediatric TB and HIV clinics, the latter currently servicing approximately 800 children. Since its inception, AHC has been closely associated with Hasbro Children s Hospital and Brown University through partnerships initiated by Dr. David Pugatch and continued by Dr. Randall Rockney. The currently available Brown Medical School elective BioMed 467 Pediatrics in a Developing Country: Cambodia is highly desired, and pediatric residents at Hasbro are encouraged to spend a month rotation at AHC during their training. Rotating medical students and residents are further encouraged to undertake educational, research, or community-based projects during their stay under the leadership of local faculty including Dr. Soeung Seitaboth who directs the pediatric HIV program and is a prior trainee of the Fogarty AIDS Training and Research Program at Brown University. Hospital rounds and clinical records are recorded in the English language. Information from patient files, including admission and follow-up data, is routinely entered into an HIV-specific database that can be accessed to provide de-identified information for use in quality improvement projects and chart reviews. Mentor: Mentorship will be provided by Dr. Rami Kantor. Dr. Kantor is an Assistant Professor of Medicine in the Division of Infectious Diseases at the Alpert School of Medicine at Brown University and an expert in the area of HIV drug resistance, with numerous prior publications in this area conducted in partnership with overseas institutions. He recently completed a study in western Kenya on treatment failure misclassification based on immunologic criteria, published in Clinical Infectious Diseases (Clin Infect Dis, 2009; 49:454-62). Dr. Kantor will serve as primary mentor for this project, advising on study design, data collection, and statistical analysis. Additional mentorship will be provided by Dr. Elizabeth Dufort. Dr. Dufort is an Assistant Professor of Pediatrics in the Division of Pediatric Infectious Diseases at the Alpert School of Medicine at Brown University, and an expert in the care of children and adolescents with HIV. She has extensive experience working in resource-limited settings, and has recently completed work on a study of antiretroviral therapy failure from
2 a large cohort of children in Western Kenya. She will provide assistance in analysis of collected data with a focus on factors relevant to care of HIV-infected children in these settings. Additional on-site guidance and support will be provided by Dr. Soeung Seitaboth, Director, Pediatric HIV Services, Angkor Hospital for Children. Finally, support is also being provided by Dr. Herb Harwell, Associate Professor, Division of Infectious Diseases, Brown University. Dr. Harwell is an experienced pediatric and adult infections diseases clinician, currently a consultant for the Clinton Foundation and based in Southeast Asia. He has been collaborating with researchers in Cambodia since Background and Significance: Globally, an estimated 2 million children under the age of 15 years are living with HIV/AIDS. While the majority resides in sub-saharan Africa, South and Southeast Asia account for up to 140,000 of these cases. Cambodia has the second-highest HIV prevalence in Southeast Asia, currently estimated at 67,000-84,000 total cases and accounting for 0.8% of the population. Among antenatal clinic (ANC) attendees, HIV prevalence was last estimated at 1.4-5% in % of HIV-infected pregnant women have access to antiretroviral (ARV) medications for the prevention of mother-to-child transmission (PMTCT), and only 9.8% of ANC clinics offer HIV counseling and testing. As a result, an estimated 4,400 children under the age of 15 are currently living with HIV/AIDS. Combination antiretroviral therapy (ART) became available in 2003 and by the end of 2007, 2,541 children were receiving ART (1). In resource-rich settings, HIV-infected children receiving ART are monitored with routine CD4 and HIV viral load (VL) testing at each visit. This allows for the detection of treatment failure manifesting as persistently elevated VL despite good adherence to the prescribed medication regimen, typically defined as >6 months of elevated VL (2). In resource-limited areas where VL assays are not available, clinical and immunologic monitoring may be the only available means for detection of ART failure. Current WHO guidelines suggest that VL measurement is not recommended for decision-making on initiation or regular monitoring of ART in resource-limited settings, but rather be reserved for scenarios of discordance in clinical or immunologic parameters (3). The rationale for this recommendation is that a precise threshold of virologic replication predicting clinical failure in children is not known, and that resources should be reserved when possible. Instead, failure of an ART regimen is identified by immunologic and clinical monitoring in most resource-limited settings. WHO guidelines define immunologic treatment failure as: 1) development of age-related severe immunodeficiency (as determined by age-related CD4 value) after a period of initial recovery, 2) new progressive age-related severe immunodeficiency, or 3) rapid decline of CD4 value below the threshold of age-related severe immunodeficiency. WHO guideline definitions of clinical treatment failure include any new WHO clinical stage 3 or 4 events in a child receiving ART. Both definitions require >24 weeks of consistent therapy with ensured adherence and adequate treatment of malnutrition and intercurrent opportunistic infections or immune reconstitution inflammatory syndrome events (3). Concern has been raised that clinical and immunologic parameters may not be sufficiently sensitive to detect virologic failure in adults receiving ART, and that delay in recognition may result in increased acquisition of drug resistant mutations as well as increased morbidity and mortality (4-5). Conversely, patients categorized as failing ART by clinical and immunologic criteria may in fact be fully suppressed and therefore
3 switched to 2 nd line regimens inappropriately (6-8). Whether the same is true in HIVinfected children is not clear. Preliminary data from our group has shown that among a cohort of 117 Kenyan children aged 0 18 years who were assessed by on-site clinicians as failing ART, 25% actually had undetectable HIV viral loads and would likely have been inappropriately switched to second-line ARV regimens had virologic monitoring not been performed (9). Similar rates of misclassification may also be occurring in other resource-limited settings outside of sub-saharan Africa. Data from the Kenyan cohort did not allow assessment of virologic failure in children without clinical or immunologic failure since VL monitoring was not routinely performed. Whether misclassification can be predicted based on additional parameters, such as patient demographics, ARV regimen, age, or comorbidity is also unknown. Additional insight into these issues may impact future recommendations for treatment monitoring of HIV-infected children receiving ART in resource-limited settings. The AHC site offers an excellent opportunity for investigation of these questions, as viral loads are determined at 6 month intervals for all children receiving ART. Objectives and Specific Aims: 1) To identify the frequency of misclassification of virologic failure in children receiving ART at the HIV clinic based at Angkor Hospital for Children in Siem Reap, Cambodia. a. To determine the proportion of children that are incorrectly identified as failing ART by clinical and immunologic criteria when in fact the HIV viral load has remained undetectable. b. To determine the proportion of children that are incorrectly identified as NOT failing ART by clinical and immunologic criteria when in fact the viral load has remained persistently detectable. 2) To describe the characteristics of children who are misclassified by immunologic and clinical criteria. a. To identify factors that may predict misclassification, which will therefore allow prioritization of viral load monitoring in those children at highest risk of misclassification. b. To describe the antiretroviral resistance patterns of children misclassified by current WHO criteria. Methods/Data Collection Procedures: This study will be a retrospective observational study of de-identified data from the AHC HIV clinic cohort. All HIV-infected pediatric patients aged 6m to 18y receiving combination ART for 6 months who had HIV viral load determined while on therapy between 1 January 2007 and 1 January 2010 will be included. Patients will be excluded if no viral load assay was performed after receipt of 6 months of a stable regimen. Data from clinical charts will be collected on age, gender, death, and most recent encounter date. In children defined by WHO guidelines as failing ART by either immunologic or clinical critera, or in whom the plasma VL is not fully suppressed, data
4 on WHO stage, ART regimen, CD4 count and percentage, history of treatment with ARVs for PMTCT, and history of treatment for active tuberculosis with a rifampicincontaining regimen while receiving ART will be collected from the time period before, during, and after the determination of ART failure was made up to the time of data collection cutoff on 1 January Antiretroviral resistance raw data and profiles obtained at the time of virologic failure will also be recorded. Virologic failure will be defined as a viral load above the limit of detection of the utilized assay on a single occasion in children receiving ART for >6 months. Virologic suppression will be defined as viral load results below the limit of detection of the utilized assay. During data analysis, additional viral load cutoffs of <1,000 (low) and <5,000 (high) will be analyzed to account for low level virologic replication (blips) that may not represent ongoing virologic failure. Clinical and immunologic failure will be defined as outlined by the WHO guidelines for the antiretroviral therapy of HIV infection in infants and children (3). Misclassification will be defined as a child meeting WHO clinical or immunologic, but not virologic, definition of failure OR a child NOT meeting WHO clinical nor immunologic definition of failure but with a detectable viral load. Institutional Review Board (IRB) approval will be obtained from Brown University and Angkor Hospital for Children prior to the collection of protected health information. Planned dates of travel to Cambodia are 1) April 12 May 7, 2010, and 2) 8 weeks from August September, Data Analysis: Primary outcome will be defined as misclassification of treatment failure as defined by clinical and immunologic, each vs. virologic criteria. Descriptive analysis of the cohort will be performed with analysis of variance methodologies by age group based on WHO age-based criteria for immunologic monitoring as follows: 1) < 5 years, 2) 5 12 years, and 3) years of age. Logistic regression analysis will be used to identify associations between recorded clinical, laboratory and demographic data and likelihood of misclassification of failure. Identified associations will be tested using prediction models to determine whether a subset of children may be reliably identified as high risk for misclassification of treatment failure and therefore constitute a group in whom virologic testing should be recommended. Plan for Dissemination: Findings from this project will be presented in the following manner, in close cooperation with our Cambodian partners. 1) Presentation at a bi-weekly lunch conference at Angkor Hospital for Children. 2) Presentation in Cambodia at a future national HIV conference (not yet scheduled). 3) Presentation at Brown Center for Aids Research (CFAR) Friday afternoon research-in-progress conference. 4) Abstract submission to an international meeting of the IDSA (October, 2010), CROI (February, 2011), or IAS (July, 2011).
5 5) Manuscript submission to a peer-reviewed journal such as Clinical Infectious Diseases, Pediatric Infectious Diseases Journal, or AIDS. Detailed Budget: Airfare: Providence to Siem Reap, Cambodia $2,800 April May and August September, 2010 $1,400 round-trip Accommodation in Siem Reap $1350 $15/day x 90d Biostatistics consultation $500 Communications: Internet access $5/day x 90 days $450 Cellular phone $30/month x3 months $90 TOTAL $5,190 Sources: 1. UNAIDS/WHO Epidemiological Fact Sheets on HIV and AIDS, 2008 Update. Accessed at on 1/23/ Working Group on Antiretroviral Therapy and Medical Management of HIV- Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009; p Available at 3. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access, recommendations for a public health approach Meya, D. et al, Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical, and CD4 cell count criteria. J Int AIDS Soc, 2009; 12:3 5. Chaiwarith, R. et al., Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis, 2007; 11: Kantor R, et al. Misclassification of First-line Antiretroviral Treatment Failure based on Immunological Monitoring of HIV-infection in Resource-Limited Settings. Clin Infect Dis, 2009; 49: Meya, D., et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc, : Reynolds, S.J., et.al., Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS, : Dufort E.M., Winstone M. Nyandiko, and Rami Kantor. Unpublished data.
Objective: Specific Aims:
Title: Retention to Care of HIV pregnant females in Kumasi, Ghana Brown Faculty: Aadia Rana, MD. Assistant Professor of Medicine in Division of Infectious Diseases, Awewura Kwara, Assistant Professor of
More informationHIV Drug Resistance (HIVDR)
Technical Guidance Note for Round 10 Global Fund HIV Proposals HIV Drug Resistance (HIVDR) Rationale for including HIVDR prevention and assessment in the proposal June 2010 As access to ART services expands,
More informationTechnical guidance for Round 9 Global Fund HIV proposals
Technical guidance for Round 9 Global Fund HIV proposals Broad Area Service Delivery Area TREATMENT Prevention and assessment of HIV drug resistance (HIVDR) This technical brief provides key information
More informationModule 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs
Module 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with the basic concepts of
More informationPaediatric and Adolescent HIV Research Grant Programme
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Paediatric and Adolescent HIV Research Grant Programme Call for Letter of Intent Table of Contents I. GRANT INFORMATION... 2
More informationInnovative Approaches for Eliminating Mother-to-Child Transmission of HIV
Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV Community Mentor Mothers: Empowering Clients Through Peer Support A Spotlight on Malawi COMMUNITY MENTOR MOTHERS 1 Optimizing HIV
More informationTechnical Guidance Note for Round 11 Global Fund HIV Proposals
Technical Guidance Note for Round 11 Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including HIVDR prevention and assessment in the proposal Situation analysis As access
More informationPrioritized research questions for adolescent HIV testing, treatment and service delivery
Prioritized research questions for adolescent HIV testing, treatment and service delivery The World Health Organization (WHO) and the Collaborative Initiative for Paediatric HIV Education and Research
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationGoal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84
Clinical guidelines across THE CONTINuUM OF CARE: LINKING PEOPLE DIAGNOSEd WiTH hiv infection to hiv care and treatment 06 6.1 Introduction 84 6.2 Good practices for linkage to care 84 6.3 General care
More informationWHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean
WHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean Giovanni Ravasi Pan-American Health Organization, Brazil ravasigi@paho.org Regional Consultation on HIV
More informationAntiretroviral therapy for adults and adolescents KEY MESSAGES. HIV/AIDS Department BACKGROUND
KEY MESSAGES New WHO Recommendations: Antiretroviral therapy for adults and adolescents The World Health Organization (WHO) is revising its guidelines on antiretroviral therapy (ART) for adults and adolescents.
More informationDr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018
Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018 1 Number of young people living with HIV (aged 15 19 years) by mode of HIV acquisition, 25 countries,*
More informationManagement of Antiretroviral Treatment (ART) and Long-Term Adherence to ART
Thailand s Annual International Training Course (AITC) 2017 Management of Antiretroviral Treatment (ART) and Long-Term Adherence to ART I. Proposal Title: Management of Antiretroviral Treatment (ART) and
More informationEXPRESSION OF INTEREST New Horizons Advancing Pediatric HIV Care Donation Program
EXPRESSION OF INTEREST New Horizons Advancing Pediatric HIV Care Donation Program Background With the release of the 2014 UNAIDS 90-90- 90 treatment target, programs are expected to scale- up efforts to
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationProgress against the HIV Epidemic: is the end in sight?
Progress against the HIV Epidemic: is the end in sight? Christine Hughes, BscPharm, PharmD, FCSHP Professor, Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Clinical Pharmacist, Northern
More informationOverview of Paediatric HIV Treatment and Prevention: From Then to Now. Peter Mugyenyi, Joint Clinical Research Centre Kampala, Uganda
Overview of Paediatric HIV Treatment and Prevention: From Then to Now Peter Mugyenyi, Joint Clinical Research Centre Kampala, Uganda Outline The plight of HIV infected children (1980s and 1990s) Trends
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationAccelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges
Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges George Siberry, MD, MPH OGAC Senior Technical Advisor for Pediatrics March, 2016 Compared to Adults, Children (
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More informationtargets for HIV-positive children
Accessing antiretroviral therapy (ART) is a matter of life and death for HIV-infected children. Without ART, half of children born with HIV die by the age of two years, and 80 percent die by the age of
More informationWomen In Science Scholars Annual Meeting Highlights October 3, 2016
Women In Science Scholars Annual Meeting Highlights October 3, 2016 Marilyn Foote-Hudson, Executive Director of the North Carolina GlaxoSmithKline Foundation welcomed the audience. She recognized the scholars
More informationTOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV
TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four
More informationAnti Retroviral Traitment (ARVs)
Anti Retroviral Traitment (ARVs) IEC material for People With Disabilities UPHLS - 2015 - Anti Retroviral Traitment Booklet Produced by AZ MEDIA No part of this publication may be reproduced without prior
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationSafe Generations Harnessing Implementation Science to Assess the Impact of Option B+ in Swaziland
Safe Generations Harnessing Implementation Science to Assess the Impact of Option B+ in Swaziland Background and Rationale In 2015, the World Health Organization (WHO) endorsed universal treatment for
More informationWhat we need to know: The role of HIV surveillance in ending the AIDS epidemic as a public health threat
3 rd Global HIV/AIDS Surveillance Meeting What we need to know: The role of HIV surveillance in ending the AIDS epidemic as a public health threat Peter D Ghys (UNAIDS) Daniel Low-Beer (WHO) Irum Zaidi
More informationSurveillance of Recent HIV Infections: Using a Pointof-Care Recency Test to Rapidly Detect and Respond to Recent Infections
Surveillance of Recent HIV Infections: Using a Pointof-Care Recency Test to Rapidly Detect and Respond to Recent Infections WHAT WAS THE PROBLEM? As countries make progress towards universal coverage of
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030
ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030 1. WE, the Heads of State and Government of the Association of Southeast
More informationDr. Mercy Maina, Bpharm Pharmacovigilance Pharmacist USAID- AMPATH 1/17/2014 1
Dr. Mercy Maina, Bpharm Pharmacovigilance Pharmacist USAID- AMPATH 1 Provide a brief description of AMPATH Give a background and description of the project Review the preliminary results Discuss the challenges
More informationAETC Needs Assessment Question Bank
AETC Needs Assessment Question Bank ABOUT YOUR AGENCY/CLINIC What are the general characteristics of your patient/client population? Race, ethnicity, gender, age, socioeconomic status, cultural identities,
More informationUganda. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)
WHO/CDS/HIV/18.50 Demographic and socioeconomic data Uganda HIV Country Pro le: 2017 42.9 million Total population (2017) 1 820 US$ GNI per capita, PPP (2017) 343 Maternal mortality per 100 000 live births
More informationEver enrolled Currently enrolled Ever on ART Sub- County Adults Peds Total Adults Peds Total Adults Peds Total Adults Peds Total
In September 2004, the Kenya Medical Research Institute (KEMRI) and University of California, San Francisco (UCSF), supported by the President s Emergency Plan for AIDS Relief (PEPFAR)/Centers for Disease
More informationPatient Involvement in Pharmacovigilance: The Development of an HIV Peer Educator Program
Patient Involvement in Pharmacovigilance: The Development of an HIV Peer Educator Program Mercy Maina Bpharm, MPH, Pgdip Clinical Pharmacy, Moi Teaching and Referral Hospital, Eldoret Kenya Rakhi Karwa
More informationInternational Training Course on Comprehensive Care Management for Children and Adolescents living with HIV/AIDS
Thailand s Annual International Training Course (AITC) Course Information International Training Course on Comprehensive Care Management for Children and Adolescents living with HIV/AIDS 11 22 March 2019
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationADOLESCENTS AND HIV:
Elizabeth Glaser Pediatric AIDS Foundation Until no child has AIDS. Photo by Eric Bond/EGPAF, 2015 ADOLESCENTS AND HIV: PRIORITIZATION FOR ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION PROGRAMS, ADVOCACY
More informationTo provide you with the basic concepts of HIV prevention using HIV rapid tests combined with counselling.
Module 2 Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Learning Objectives To provide you with the basic concepts of HIV prevention using HIV rapid
More informationGLOBAL AIDS MONITORING REPORT
KINGDOM OF SAUDI ARABIA MINISTRY OF HEALTH GLOBAL AIDS MONITORING REPORT COUNTRY PROGRESS REPORT 2017 KINGDOM OF SAUDI ARABIA Submission date: March 29, 2018 1 Overview The Global AIDS Monitoring 2017
More informationFactors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa
Factors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa Dvora Joseph Davey 1, 2, PhD, Zulfa Abrahams 2, PhD 1 BroadReach, South Africa
More informationProjected Demand for HIV Diagnostic Tests
Projected Demand for HIV Diagnostic Tests John Stover, Yu Teng, Adebiyi Adesina, Eline Korenromp On behalf of the Diagnostics Forecasting Technical Working Group (CDC, CHAI, GFATM, PfSCM, UNAIDS, UNICEF,
More informationProgramme. Co-Chairs. Take the conversation further online follow AIDS #AIDS2016
EVIDENCE TOACTION This session will highlight the essential role that collaborative research plays in improving public sector policies and services for HIV treatment and prevention. Across southern Africa
More informationVol. 5, No. 18 Spring 2010
Vol. 5, No. 18 Spring 2010 IN THIS ISSUE: Snapshot Knowledge Hub activities to date, in numbers Knowledge Hub Calendar Find out about training workshops and other upcoming events Knowledge Hub in Review
More informationTunisian recommendations on ART : process and results
Second Arab Congress of Clinical Microbiology and Infectious Diseases May 24-26, 2012. Tunisian recommendations on ART : process and results M. BEN MAMOU UNAIDS Email: BenmamouM@unaids.org M. CHAKROUN
More informationHIV Drug Resistance South Africa, How to address the increasing need? 14 Apr. 2016
HIV Drug Resistance South Africa, How to address the increasing need? 14 Apr. 2016 1 Thus the HIV DR needs to focus on prevention and then diagnostic capacity to 1 st provide VL monitoring for early &
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationMichael Healy August 8, 2012 Irving CRC Research Proposal. 1. Study Purpose and Rationale
Michael Healy August 8, 2012 Irving CRC Research Proposal Prevalence of diarrhea and gastrointestinal infection in severely malnourished Human Immunodeficiency Virus (HIV) infected children in Durban,
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationVol. 5, No. 20 Fall 2010
Vol. 5, No. 20 Fall 2010 IN THIS ISSUE: Snapshot Knowledge Hub activities to date, in numbers Knowledge Hub Calendar Find out about training workshops and other upcoming events Knowledge Hub in Review
More informationScaling Up Routine Viral Load in Resource Limited Settings. MSF experience in Zimbabwe
Scaling Up Routine Viral Load in Resource Limited Settings MSF experience in Zimbabwe Outline 1. Why do we need VL 2. What are the barriers to roll out 3. MSF experience 4. Summary samumsf.org 1. Why do
More informationConcept note. 1. Background and rationale
Concept note Inter-Country Workshops for Strengthening Regional and National Human Capacity to Accelerate Scaling up of National PMTCT and Paediatric Care, Support and Treatment Programmes TOWARDS UNIVERSAL
More informationAbout FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.
Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose
More informationThe human immunodeficiency virus/acquired immune
Vol. 7(4), pp. 44-48, May 2015 DOI: 10.5897/JAHR2014.0320 Article Number: 70F676253212 ISSN 2141-2359 Copyright 2015 Author(s) retain the copyright of this article http://www.academicjournals.org/jahr
More informationInnovative Approaches for Eliminating Mother-to-Child Transmission of HIV. Male Champions: Men as Change Agents in Uganda MALE CHAMPIONS
Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV Male Champions: Men as Change Agents in Uganda MALE CHAMPIONS 1 Optimizing HIV Treatment Access for Pregnant and Breastfeeding
More informationImproving accessibility to antiretroviral drugs: A south-south collaboration
Improving accessibility to antiretroviral drugs: A south-south collaboration Jaideep A Gogtay MD Cipla Ltd Mumbai jgogtay@cipla.com Adults and children estimated to be living with HIV at the end of 2000
More informationAttrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program
Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program Sirinya Teeraananchai 1,2, Thanyawee Puthanakit 1,3,4, Suchada Chaivooth
More informationWHO HIV Drug Resistance Strategy
WHO HIV Drug Resistance Strategy Boston, 27 February 2011 Background Global ART scale-up has been a remarkable achievement benefiting over 5.2 million individuals in resource limited settings Maintaining
More informationSTRENGTHENING SOCIAL ACCOUNTABILITY
Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV: Strengthening Social Accountability Through Health Advisory Committees in Malawi 1 The Optimizing HIV Treatment Access for Pregnant
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationThe Unfinished Business Project in South West Uganda Closing the Adult- Pediatric Treatment Gap
Photo: Eric Bond/EGPAF, 215 Elizabeth Glaser Pediatric AIDS Foundation The Unfinished Business Project in South West Uganda Closing the Adult- Pediatric Treatment Gap Background While Uganda achieved significant
More informationPaediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff
Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme- 20171031[2].tiff Mo Archary King Edward VIII Hospital / UKZN Paediatric Infectious Diseases Unit Overview State
More informationGLOBAL STATISTICS FACT SHEET 2015
FACT SHEET 2015 GLOBAL STATISTICS 15.8 people accessing antiretroviral therapy (June 2015) 36.9 [34.3 41.4 ] people globally were living with HIV (end 2014) 2 [1.9 2.2 ] people became newly infected with
More informationSummary. Project title: HIV/AIDS and Tuberculosis Control Project Cooperation scheme: Technical Cooperation Total cost:approximately 452 million yen
1. Outline of the Project Country: Zambia Issue/Sector:Health Division in charge:infectious Disease Control Division, Human Development Dept. (R/D): 3. 2001 3. 2006 Summary Evaluation conducted by: Takuya
More informationRESEARCH. All Photos: Eric Bond/EGPAF,2017
RESEARCH All Photos: Eric Bond/EGPAF,2017 The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a recognized global leader in the fight to end pediatric HIV/AIDS through research, advocacy, and delivery
More informationEnhanced Skills Program. in HIV/AIDS
BC Centre for Excellence in HIV/AIDS University of British Columbia Enhanced Skills Program in HIV/AIDS 3-month Postgraduate Training Program BC Centre for Excellence in HIV/AIDS UBC Enhanced Skills Program
More informationEACS HIV Summer School PRELIMINARY PROGRAMME
EACS HIV Summer School Thursday, August 30, 2018 Monday, September 3, 2018 Montpellier, France This 5-day residential course is designed for clinicians experienced in HIV management who want an update
More informationManaging Transition from Pediatric to Adolescent to Adult HIV Care
Managing Transition from Pediatric to Adolescent to Adult HIV Care Allyson McKenney, MD Ilana Cohen Julie Parent Disclosure Dr. McKenney received speaker fees from Johnson & Johnson. Page 2 United Nations:
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationPregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20
Introduction Pregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20 Proportions HIV infections 19% amongst adolescents (- 29.5% nationally 15
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationWHO HIV Drug Resistance Prevention and Assessment Strategy. Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team
WHO HIV Drug Resistance Prevention and Assessment Strategy Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team Eastern & Southern African Countries (ESA) 2 The HIV epidemic
More informationFinancial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment
Financial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment Joint WHO & UNAIDS Consultation with Pharmaceuticals and Stakeholders November 05 2012 Lara Stabinski, MD, MPH Medical
More informationProgram Overview. Supported by PEPFAR/HRSA Grant Number U91HA06801
Program Overview Supported by PEPFAR/HRSA Grant Number U91HA06801 Program Goal To contribute to health systems strengthening in African partner countries by developing a leadership training program targeting
More informationCare and Treatment of Children and Adolescents with HIV - The Barbados Experience.
Care and Treatment of Children and Adolescents with HIV - The Barbados Experience. M. Anne St John Consultant, Department of Paediatrics Queen Elizabeth Hospital, Barbados Hon Professor, Child Health,
More informationCote D'Ivoire. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)
WHO/CDS/HIV/18.50 Demographic and socioeconomic data Cote D'Ivoire HIV Country Pro le: 2017 24.3 million Total population (2017) 3 820 US$ GNI per capita, PPP (2017) 645 Maternal mortality per 100 000
More informationQuality of medical services and their impact on the cascade of cares in HIV infection, at national level Roundtable discussion
Quality of medical services and their impact on the cascade of cares in HIV infection, at national level Roundtable discussion Mariana Mărdărescu MD PhD Adrian Streinu-Cercel MD PhD HC Mike Youle MD PhD
More informationCHAI Cambodia: HIV Program Update NCHADS Annual Operational Comprehensive Planning Workshop Dec 3, 2012
CHAI Cambodia: HIV Program Update NCHADS Annual Operational Comprehensive Planning Workshop Dec 3, 2012 1 CHAI areas of collaboration with NCHADS 1. HIV Program Context: Background 1. emtct 2. Drug Access
More informationInstitute of Medicine. The President s Emergency Plan Strategic Information April 21, 2005
Institute of Medicine The President s Emergency Plan Strategic Information April 21, 2005 Questions of Interest What is the framework to evaluate The Emergency Plan? Measuring impact and outcomes Evidence-based
More informationRegistration for INTEREST 2019 is now open!
INTEREST - 13th International Conference on HIV Treatment, Pathogenesis, and Prevention Research in Resource-Limited Settings 14-17 May 2019, Accra, Ghana The PREMIER scientific platform for researchers
More informationUpdate on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines
WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan
More informationADOLESCENT MEDICINE SUBSPECIALTY RESIDENCY/FELLOWSHIP PROGRAM DESCRIPTION
ADOLESCENT MEDICINE SUBSPECIALTY RESIDENCY/FELLOWSHIP PROGRAM DESCRIPTION DIVISION OF ADOLESCENT HEALTH AND MEDICINE DEPARTMENT OF PEDIATRICS BRITISH COLUMBIA CHILDREN S HOSPITAL UNIVERSITY OF BRITISH
More informationKathryn Schnippel 1*, Constance Mongwenyana 1, Lawrence C Long 1 and Bruce A Larson 2
Schnippel et al. BMC Infectious Diseases (2015) 15:46 DOI 10.1186/s12879-015-0778-2 RESEARCH ARTICLE Open Access Delays, interruptions, and losses from prevention of mother-to-child transmission of HIV
More informationHIV in the United Kingdom: 2009 Report
HIV in the United Kingdom: 2009 Report Key findings The number of people living with HIV in the UK continues to rise, with an estimated 83,000 infected at the end of 2008, of whom over a quarter (27%)
More informationDRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES
DRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES April 2005 Summary: Millions of children in developing countries are affected by the HIV/AIDS pandemic. Despite significant international
More informationHIV TESTING IN THE ERA OF TREATMENT SCALE UP
HIV TESTING IN THE ERA OF TREATMENT SCALE UP Kevin M. De Cock he ways in which global responses to HIV/AIDS have differed from responses to other infectious diseases have been extensively discussed in
More informationIn 2013, around 12.9 million people living with HIV had access to antiretroviral therapy.
F A C T S H E E T 2014 GLOBAL STATISTICS People living with HIV In 2013, there were 35 [33.2 37.2 ] people living with HIV. - Since the start of the epidemic, around 78 [71 87 ] people have become infected
More informationMDS Mentorship Experience
MDS Mentorship Experience MENTOR: CARRIE KOVARIK, MD UNIVERSITY OF PENNSYLVANIA MENTEE: MONICA RANI, MD UNIVERSITY OF MINNESOTA NORTHWESTERN UNIVERSITY From Philadelphia ------ > Kampala, Uganda COAT
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationHIV Quality Improvement Initiatives in Mozambique
HIV Quality Improvement Initiatives in Mozambique HEALTHQUAL INTERNATIONAL: ACLN 2012 Kampala, Uganda Dr. Mussa Calu, MD Joseph Lara, MPH Dr. Isabel Pereira, MD MPH KEY HIV/AIDS INDICATORS 1. HIV Prevalence
More informationYoung Mothers: From pregnancy to early motherhood in adolescents with HIV
Young Mothers: From pregnancy to early motherhood in adolescents with HIV Lisa L. Abuogi, MD, MSc Assistant Professor University of Colorado, Denver 8 th HIV and Women Workshop March 2, 2018 Boston, MA
More informationThe Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT
The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT Peter McDermott Managing Director, CIFF 19 th Board meeting, Geneva 6 th May 2009 Investment Criteria Measurable...change
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationHIV EPIDEMIC UPDATE: FACTS & FIGURES 2012
HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012 Number of Cases Note: In this surveillance report, HIV cases include persons reported with HIV infection (non-aids), advanced HIV (non-aids) and AIDS within a
More information1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other
Title: Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review Contents 1. PICO question... 1 2. Search
More informationExpert Clients Improve HIV/AIDS Care and Address Stigma in Malawi
Abstract no. TUPE414 Expert Clients Improve HIV/AIDS Care and Address Stigma in Malawi Authors: Onani Bokosi 1, Erin Linsky Graeber 1, Carol Makoane 2 1 PCI Malawi, 2 PCI Washington, DC Background Project
More information